Lesson plan

Neuropathix

Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics. In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019 along with other therapeutic agents that prevent neuropathic pain, mitochondrial dysfunction, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol. Neuropathix family of monotherapeutic small molecules are focused on treating oxidative stress-related diseases, inflammation, chronic pain management and neurodegenerative disorders. In late 2021, Neuropathix subsidiary Kannalife, was awarded a non-dilutive three-year $2.97 Million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institutes of Health (NIH). The three-year study grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for enhanced pain management and provides funding specifically in the Development of KLS-13019 for Neuropathic Pain. In 2024, The Michael J.…

Back to article

Article summary

Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics. In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019 along with other therapeutic agents that prevent neuropathic pain, mitochondrial dysfunction, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol. Neuropathix family of monotherapeutic small molecules are focused on treating oxidative stress-related diseases, inflammation, chronic pain management and neurodegenerative disorders. In late 2021, Neuropathix subsidiary Kannalife, was awarded a non-dilutive three-year $2.97 Million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institutes of Health (NIH). The three-year study grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for enhanced pain management and provides funding specifically in the Development of KLS-13019 for Neuropathic Pain. In 2024, The Michael J.…

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.